Edgewise Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 2 | -$0.34 | -$0.34 | -$0.34 |
| Q2 2024 | 6 | -$0.41 | -$0.34 | -$0.37 |
| Q3 2024 | 2 | -$0.39 | -$0.39 | -$0.39 |
| Q1 2025 | 5 | -$0.38 | -$0.38 | -$0.38 |
| Q2 2025 | 5 | -$0.42 | -$0.42 | -$0.42 |
| Q3 2025 | 5 | -$0.45 | -$0.45 | -$0.45 |
| Q4 2025 | 5 | -$0.50 | -$0.50 | -$0.50 |
Edgewise Therapeutics, Inc. Earnings Date And Information
Edgewise Therapeutics, Inc. last posted its earnings results on Thursday, August 8th, 2024. The company reported $-0.34 earnings per share for the quarter, topping analysts' consensus estimates of $-0.36 by $0.02. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Edgewise Therapeutics, Inc. has generated $-2 earnings per share over the last year ($-1.57 diluted earnings per share) and currently has a price-to-earnings ratio of -29. Edgewise Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based on prior year's report dates.
Edgewise Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/08/2024 | Q2 2024 | -$0.36 | -$0.34 | 0.02 | $0 | $0 |
| 05/09/2024 | Q1 2024 | -$0.39 | -$0.33 | 0.06 | $0 | |
| 02/22/2024 | Q4 2023 | -$0.44 | -$0.47 | -0.03 | $2.25 M | |
| 11/09/2023 | Q3 2023 | -$0.40 | -$0.41 | -0.01 | $0 | |
| 08/10/2023 | Q2 2023 | -$0.41 | -$0.34 | 0.07 | $0 | |
| 05/11/2023 | Q1 2023 | -$0.37 | -$0.31 | 0.06 | $0 | |
| 02/23/2023 | Q4 2022 | -$0.36 | -$0.26 | 0.1 | $0 | |
| 11/03/2022 | Q3 2022 | -$0.36 | -$0.32 | 0.04 | $0 | |
| 08/04/2022 | Q2 2022 | -$0.34 | -$0.32 | 0.02 | $0 | |
| 05/11/2022 | Q1 2022 | -$0.29 | -$0.29 | 0 | $0 | |
| 02/24/2022 | Q4 2021 | -$0.28 | -$0.26 | 0.02 | $0 | |
| 11/10/2021 | Q3 2021 | -$0.22 | -$0.26 | -0.04 | $0 | |
| 08/09/2021 | Q2 2021 | -$0.18 | -$0.21 | -0.03 | $0 | |
| 05/13/2021 | Q1 2021 | -$0.16 | -$4.37 | -4.21 | $0 | |
| 12/30/2020 | Q4 2020 | -$0.31 | $0 | |||
| 09/29/2020 | Q3 2020 | -$0.18 | $0 | |||
| 06/29/2020 | Q2 2020 | -$0.19 | $0 | |||
| 03/30/2020 | Q1 2020 | -$0.16 | $0 |
Edgewise Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Edgewise Therapeutics, Inc.'s earnings date?
Edgewise Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based off last year's report dates.
-
Did Edgewise Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Edgewise Therapeutics, Inc. (:EWTX) reported $-0.34 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.36 by $0.02.
-
How can I listen to Edgewise Therapeutics, Inc.'s earnings conference call?
The conference call for Edgewise Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Edgewise Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Edgewise Therapeutics, Inc.'s latest earnings report can be read online.
-
How much profit does Edgewise Therapeutics, Inc. generate each year?
Edgewise Therapeutics, Inc. (:EWTX) has a recorded net income of $0. Edgewise Therapeutics, Inc. has generated $-1.57 earnings per share over the last four quarters.
-
What is Edgewise Therapeutics, Inc.'s price-to-earnings ratio?
Edgewise Therapeutics, Inc. (:EWTX) has a price-to-earnings ratio of -29 and price/earnings-to-growth ratio is -0.29.
